Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with ...

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...